An Introduction to Lung Cancer
In some Western countries, the frequency and mortality of lung cancer are decreasing due to decades of public education and tobacco control policies, even though it still remains a major cause of mortality worldwide. Expert video highlights, insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the ever-changing landscape. To learn more about how the latest developments impact on patient outcomes view our expert-led learning activities.
Lung Cancer Content
MET Exon 14 Skipping Alterations in NSCLC: Current Understanding and Therapeutic Advances
Oncology & Hematology Review (US). 100-10 DOI: https://doi.org/10.17925/OHR.2021.16.2.100
Advanced non-small cell lung carcinoma (NSCLC) treatment paradigms have evolved during the past decade. Identification of tumor-specific molecular alteration in cancer driver genes has led to the development of targeted therapies.1–3 Most of the tumors harboring such alterations are sensitive to tyrosine kinase inhibitor (TKI) drugs, making such oncogenic drivers promising targets for the development of […]
Radiation-induced Esophagitis in Lung Cancer—A Common Problem with Limited Therapeutic Options
Oncology & Hematology Review. 2020;16(2): 95-99 DOI: https://doi.org/10.17925/OHR.2021.16.2.95
Radiation-induced esophagitis, caused by incidental damage to the mucosal lining of the esophagus during radiation therapy, is a common and clinically important toxicity in patients with lung cancer. Esophagitis generally develops 2–3 weeks after initiation of radiation therapy and presents as pain and dysphagia, which can negatively impact patient quality of life.1 Severe esophagitis requires parenteral […]
Progress in EGFR-mutant NSCLC: Where are we going?
Watch leading non-small cell lung cancer (NSCLC) experts discuss the current standard and the latest advancements in epithelial growth factor receptor (EGFR)-targeted therapy.
- Describe the rationale for and clinical trial data associated with combination therapy in first-line EGFR-mutant NSCLC
- Describe the mechanisms of resistance to third-generation EGFR-TKIs and strategies to manage drug resistance in the second-line setting
- Recall data on emerging therapeutic strategies for early-stage EGFR-mutant NSCLC and how this may impact the metastatic treatment landscape
The role of MDTs in optimizing NSCLC management:
From early disease and beyond
This activity brings together a panel of experts involved in the management of patients with non-small cell lung cancer (NSCLC) to discuss how optimal multidisciplinary team practices and communication can translate to improved patient care.
- Appraise optimal working practices for a successful multidisciplinary team (MDT) approach to the management of patients with non-small cell lung cancer (NSCLC)
- Describe communication strategies for MDT members when assessing patient needs and making treatment decisions in patients with NSCLC
- Discuss how the MDT can support patient care by identifying potential barriers to MDT working practices and by actively incorporating new research findings into NSCLC management
Ahmet Sezer, ESMO 2020 – Cemiplimab in Non-small Cell Lung Cancer and the EMPOWER-Lung 1 Trial
It was a pleasure to meet Dr Ahmet Sezer to discuss the clinical development of cemiplimab as a potential treatment for non-small cell lung cancer and key safety and efficacy findings from the EMPOWER- Lung 1 study. The late-breaking abstract, ‘EMPOWER-Lung 1: Phase 3 first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small […]
PD-1 inhibitors on the horizon for NSCLC: Current knowledge, future possibilities
Watch the footage from our Satellite Symposium at the ESMO Virtual Congress 2020, exploring novel PD-1 inhibitors on the horizon for NSCLC.
- Review the latest clinical and pre-clinical data for anti-PD-1 agents in NSCLC
- Discuss how current and emerging anti-PD-1 agents may be incorporated into the treatment landscape for NSCLC
- Summarize how to identify the patients most suitable for anti-PD-1 blockade
New frontiers in NSCLC immunotherapy
Watch leading non-small cell lung cancer (NSCLC) experts discuss immunotherapy and the emerging approaches targeting interleukin-1 (IL-1).
- Recognize the remaining challenges in terms of long-term survival for patients with NSCLC despite the availability of checkpoint inhibitors
- Describe the tumour immune cycle and the therapeutic opportunities it may provide
- Discuss the potential for reduction in cancer morbidity and mortality with IL-1-targeted agents and its implication for early treatment of NSCLC
Facing the First-line in Metastatic Non-small-cell Lung Cancer – Immunotherapy and Chemotherapy
European Oncology & Haematology. 2020;16(1):39-43 DOI: https://doi.org/10.17925/EOH.2020.16.1.39
Historically, chemotherapy represented the only available treatment for patients with advanced non-small-cell lung cancer (NSCLC) who did not show any target molecular driver, such as epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK) or the receptor tyrosine kinase ROS1. Unfortunately, limited efficacy was reported using chemotherapy alone.1 The advent of immunotherapy, a treatment based on […]
ALK Inhibitors in ALK-positive NSCLC with Central Nervous System Metastases
European Oncology & Haematology. 2020;16(1):18-21 DOI: https://doi.org/10.17925/EOH.2020.16.1.18
At initial diagnosis of metastatic disease, central nervous system (CNS) metastases are present in 22–33% of patients with anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC). After crizotinib failure, the incidence can reach up to 70%, compared with 40% in all comers.1 The presence of CNS disease is an indicator of poor prognosis in […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!